Beam’s medicine uses a technology known as base editing to activate a gene in stem cells collected from people with sickle ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including further cost cuts, as he seeks to fend off allegations of mismanagement from ...

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer reported higher-than-expected profit on Tuesday due to strong sales of COVID treatment Paxlovid, an important win for Chief Executive Albert Bourla as he faces down activist investor Starboard.

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist ...

The "Sickle Cell Disease Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering. The ...

Enrollment has finished for the Phase 3 RISE UP study, which is testing the oral therapy mitapivat in people with sickle cell ...